

Breakthrough Treatment for Pain™

SPRINT
PNS SYSTEM

David H. Rustom, MD
Clinical Assistant Professor WSU-SOM
Clinical Assistant Professor WSU-EDM
Faculty Physical Medicine and Rehabilitation Residency Program
Faculty Sports Medicine Fellowship
Attending Interventional Pain and PMGR
Rehabilitation Institute of Michigan/Detroit Medical Center
Detroit, Michigan
drustom@imc.org

SHOULDER
BACK
KNEE
NERVE TRAUMA

© 2019 Inceptivesthetics, Inc. 2019

© 2019 Inceptivesthetics, Inc. 2019

How SPRINT's 60-Day PNS Treatment May Recondition the CNS

SPRINT
PNS SYSTEM

Pathway to Chronic Pain

Inciting Event

- Neural Signaling Changes
 - Increased abnormal and spontaneous afferent signaling
 - Pain that endures after normal tissue healing
- Central Sensitization:
 - Sustained changes in central pain processing
 - Hypersensitivity to normal inputs
- Maladaptive Cortical Plasticity
 - Unbalanced sensory inputs lead to cortical remapping
 - Imbalance in nociceptive processing

SPRINT PNS (60 days)


- Improve Neural Signaling
 - INCREASE HEALTHY afferent signals in non-pain nerve fibers
- Modulate Sensitization
 - MODULATE central pain processing
 - REDUCE hypersensitivity to normal inputs
- Recondition Cortical Processing
 - REBALANCE sensory inputs to restore healthy cortical processing of nociceptive signals

Peripherally Induced Reconditioning of the CNS

© 2019 Inceptivesthetics, Inc. 2019

SPRINT
PNS SYSTEM

Percutaneous PNS Evolution



The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

SPRINT
PNS SYSTEM

PNS Then and Now

←

THEN

- Neurosurgical exposure/procedure
- Contact positioning critical
- Nerve injury/fibrosis concerns
- Focus on spinal cord stimulation
- Permanent and invasive
- Neuropathic focus
- Last resort therapy

→

NOW

- Percutaneous intervention
- Ultrasound guidance
- Remote lead placement
- Ease of use
- Low infection risk
- Durable relief following lead withdrawal
- Applications beyond neuropathic pain
- Early intervention

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.


SPRINT
PNS SYSTEM

Long Held Beliefs are Changing

- Pain Relief without paresthesia IS possible
- Anatomic vs physiologic lead placement IS beneficial
- Lower amplitudes MAY BE more effective than max tolerated
- Positive response to a nerve block is NOT predictive of PNS outcomes
- Remote lead placement CAN preferentially activate targeted nerve fibers
- Motor activation CAN result in sustained pain relief
- Medial branch stimulation VERSUS ablation may provide relief of low back pain
- Sustained relief IS commonplace following a 60-day PNS treatment

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

Rethink Your Pain Strategy™



Medications and PT Medications and PT Injections Simultaneous PNS Ablation Permanent Implant Permanent Implant Surgery Surgery

60-day implant period

No permanent implant





FDA-cleared for the treatment of chronic and acute pain

Pain relief is significant and sustained for most patients

The content of this presentation is proprietary and confidential information of SPRINT Therapeutics. ©2020. All rights reserved.




Clinical Evidence




The content of this presentation is proprietary and confidential information of SPRINT Therapeutics. ©2020. All rights reserved.


Efficacy of 60-Day PNS Treatment



Across 30+ peer-reviewed publications regarding percutaneous PNS-related clinical trials, many of which were funded in part by the Department of Defense (DoD) and the National Institutes of Health (NIH):




75% of patients reported **SIGNIFICANT** pain relief.



75% of patients reported **SUSTAINED** pain relief.

The content of this presentation is proprietary and confidential information of SPRINT Therapeutics. ©2020. All rights reserved.



Clinical Evidence Highlights SPRINT[™] PNS SYSTEM

- 30+ peer-reviewed published articles since 2001
- 3 Randomized Controlled Trials (RCTs)
 - Christopher A. Gilmore, MD et al, Percutaneous Peripheral Nerve Stimulation for the Treatment of Chronic Neuropathic Post-Amputation Pain: A Multi-Center Randomized Placebo-Controlled Trial, Regional Anesthesia and Pain Medicine, 2019
 - Wilson, R.D., Gunzler, D.D., Bennett, M.E., & Chae, J. (2014). Peripheral nerve stimulation compared with usual care for pain relief of hemiplegic shoulder pain: a randomized controlled trial, American journal of physical medicine & rehabilitation/Association of Academic Physiatrists, 93(1), 17
 - Chae, J., David, T.Y., Walker, M.E., Kirsteins, A., Elovic, E.P., Flanagan, S.R., & Fang, Z.P. (2005). Intramuscular electrical stimulation for hemiplegic shoulder pain: a 12-month follow-up of a multicenter, randomized clinical trial, American journal of physical medicine & rehabilitation, 84(11), 832-842.
- > \$30M in DoD/NIH funding
- Conference Awards
 - CNS 2020 – Top Abstract Award – Reduction of Opioid use for Low Back Pain – Dr. Mehul Desai
 - ASRA 2019 – Best of Meeting Award – 12-month Relief of Post-Amputation Pain Following Treatment With SPRINT PNS System – Dr. Chris Gilmore
 - ASPN 2019 – Best Overall Abstract Award and Clinical Science Research Award – 12-month Relief of Post-Amputation Pain Following Treatment With SPRINT PNS System – Dr. Chris Gilmore
 - NANS 2020 – Best Poster For PNS Group – Treating Greater Trochanteric Pain Syndrome with Ultrasound Guided Peripheral Nerve Stimulation – Dr. Katie Guram

The content of this presentation is proprietary and confidential information of SPRINT Therapeutics. ©2020 All rights reserved. SPRINT 10

Sustained Pain Relief SPRINT[™] PNS SYSTEM

Percutaneous PNS vs Conventional Care for Hemiplegic Shoulder Pain

First Percutaneous PNS Randomized Controlled Trial
...First demonstration of Sustained Pain Relief

78% Reported Relief 12 months after Treatment

This RCT utilized a 4 lead approach to activate the muscles surrounding the shoulder joint

Weeks	Conventional Therapies	Percutaneous PNS
0	7.5	7.5
5	6.5	3.5
10	6.0	3.5
20	6.0	3.5
30	5.5	3.5
55	4.5	2.5





Chae, et al (2005) SPRINT 11


Chae Results Replicated in Single Lead RCT SPRINT[™] PNS SYSTEM

Percutaneous PNS vs PT in the Management of Hemiplegic Shoulder Pain

Weeks	Chae 2005 - 4 Lead	Wilson 2014 - Single Lead	Physical Therapy
0	8.5	8.5	8.5
3	6.5	6.5	6.5
4	5.5	5.5	5.5
6	4.5	4.5	4.5
15	4.5	4.5	4.5
30	4.5	4.5	4.5

Wilson, et al (2014) SPRINT 12



Percutaneous PNS Shows Reduced Opioid Use 

In low back pain:

- At 3 months following 60-day percutaneous PNS therapy 73% (n=8/11) reported ≥50% reduction in opioid use (average reduction 82%)
- These substantial reductions were seen even among patients with daily baseline opioid consumption ≥ 50 milligram morphine equivalent (rated by the CDC as high-risk for opioid overdose)


<https://www.spri.com/press-releases/2019/08/06/2019-1-SPR-Poster-1.pdf>


In post-amputation pain:

- 60-day percutaneous PNS therapy demonstrates 12-month pain relief and 70 percent reduction in opioid use among those taking moderate to high doses


<https://spri.com/press-releases/2019/04/05/2019-100100>

Low back pain: n=11
Post-amputation pain: n=28


The content of this presentation is proprietary and confidential information of SPRINT Therapeutics. ©2020 All rights reserved. 



SPRINT PNS System and Patient Selection



The content of this presentation is proprietary and confidential information of SPRINT Therapeutics. ©2020 All rights reserved.

SPRINT PNS System 

Indications for Use

The SPRINT® Peripheral Nerve Stimulation (PNS) System is indicated for up to 60 days in the back and/or extremities for:


- Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain
- Symptomatic relief of post-traumatic pain
- Symptomatic relief of post-operative pain

The SPRINT PNS System is not intended to treat pain in the craniofacial region.

Chronic Pain Applications

- Complex regional pain syndrome
- Neuropathic Mononeuropathy
- Low back pain
- Inoperable joint pain
- Post-amputation pain
- Nerve or plexus trauma
- Meralgia Paresthetica
- Post-operative joint/joint-replacement pain
- Post-herniorrhaphy pain (posterior approach)
- Post decompression/transposition surgery

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU.

The content of this presentation is proprietary and confidential information of SPRINT Therapeutics. ©2020 All rights reserved. 

MicroLead Designed to Resist Infection and Migration

SPRINT
PNS SYSTEM

The MicroLead™ is a 100µm, 7-stranded wire with a 100µm layer of insulation.

The electrode surface area is 5x longer with more than 2x the surface area of a conventional cylindrical lead

Fibrotic ingrowth around the lead is intended to reduce pistoning and the potential for infection.

*Corey 1990

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

SPR 19

Excellent Safety Profile

SPRINT
PNS SYSTEM

Adverse Event	SPR Therapeutics' PNS therapy (N=410 leads in 205 subjects)
Skin irritation, erythema, blister, mild tear	13.2% (54/410)
Miscellaneous AEs	5.3% (22/410)
Granuloma	5.1% (21/410)
Pruritus (itching) at electrode exit or bandage site	4.6% (19/410)
Pain after electrode placement	3.4% (14/410)
Pressure sore/skin abrasion from lead connector block	0.7% (3/410)
Infection	0.0% (0/410)**

*Hydrogel improvements have resulted in significant reduction in skin irritation in commercial applications.
**Among data from published studies. A small number of minor infections have occurred outside of the published data.

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

SPR 20

SPRINT PNS System

SPRINT
PNS SYSTEM


- Least-invasive PNS option
- Safety enhanced by remote placement
- Short term implant may preclude the need for a permanent implant
- SPRINT *extensa*™ first and only dual lead percutaneous PNS system

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

SPR 21

SPRINT
PNS SYSTEM

**SPRINT Coding, Coverage, and Payment
SPRcare Patient Access Program**



The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

SPRINT
PNS SYSTEM

Reimbursement for PNS

Coding:

- 64555 *Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)*
 - NANS and ASIPP validated code appropriateness for percutaneous PNS lead placement

Coverage:

- Medicare has an active National Coverage Determination (NCD 160.7) allowing the use of PNS when medically necessary in patients with chronic, intractable pain.
- Commercial coverage varies by payer and plan type

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

SPR 26


SPRINT
PNS SYSTEM

SPRcare™

- Facilitating Patient Access and Expanded Payer Coverage
- Leveraging patient-based appeal rights to reduce time to implant
- Push for independent third-party reviews (at payer expense)
- Reduce or eliminate peer-to-peer calls
- SPR will use data generated from the prior authorization and appeals processes to foster positive changes in payer policy

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020. All rights reserved.

SPR 27



SPRINT
PNS SYSTEM

*The SPRINT PNS System is cleared for up to 60 days in the back and/or extremities for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the craniofacial region.

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU.

Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.

The content of this presentation is proprietary and confidential information of SPR Therapeutics. ©2020 All rights reserved.

MKT-000198 [12]

The logo is in green. Below the text is an abstract graphic of a human head and neck area, composed of a network of green and yellow lines and nodes, similar to the brain graphic in the first image.
